Inari Medical, Inc. (NASDAQ: NARI) Stock Competitors & Peer Comparison
See NARI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NARI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NARI | $79.97 | +0.00% | 4.7B | -59.24 | -$1.35 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $101.29 | +0.22% | 175.3B | 19.44 | $5.21 | +2.45% |
| MDT | $88.64 | +0.15% | 113.5B | 16.03 | $5.53 | +3.24% |
| SYK | $272.36 | +0.97% | 104.5B | 20.35 | $13.39 | +1.28% |
| BSX | $43.92 | -1.70% | 65.3B | 14.17 | $3.10 | N/A |
| EW | $86.29 | +0.65% | 49.7B | 31.96 | $2.70 | N/A |
| DXCM | $86.62 | -0.97% | 32.7B | 33.97 | $2.55 | N/A |
| GEHC | $66.63 | +0.38% | 30.1B | 14.61 | $4.56 | +0.21% |
| PHG | $24.96 | +1.67% | 24.4B | 14.26 | $1.75 | +3.97% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
NARI vs BSX-PA Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NARI's ROE is -0.00%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NARI is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
NARI vs ABT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ABT trades at $101.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ABT's P/E ratio is 19.44. In terms of profitability, NARI's ROE is -0.00%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NARI is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ABT's competition here
Medtronic plc (NYSE: MDT)
NARI vs MDT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, MDT has a market cap of 113.5B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while MDT trades at $88.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas MDT's P/E ratio is 16.03. In terms of profitability, NARI's ROE is -0.00%, compared to MDT's ROE of +0.11%. Regarding short-term risk, NARI is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
NARI vs SYK Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SYK has a market cap of 104.5B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SYK trades at $272.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SYK's P/E ratio is 20.35. In terms of profitability, NARI's ROE is -0.00%, compared to SYK's ROE of +0.16%. Regarding short-term risk, NARI is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
NARI vs BSX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BSX has a market cap of 65.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BSX trades at $43.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BSX's P/E ratio is 14.17. In terms of profitability, NARI's ROE is -0.00%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NARI is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NARI vs EW Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, EW has a market cap of 49.7B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while EW trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas EW's P/E ratio is 31.96. In terms of profitability, NARI's ROE is -0.00%, compared to EW's ROE of +0.10%. Regarding short-term risk, NARI is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for NARI.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
NARI vs DXCM Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while DXCM trades at $86.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas DXCM's P/E ratio is 33.97. In terms of profitability, NARI's ROE is -0.00%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, NARI is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for NARI.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
NARI vs GEHC Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, GEHC has a market cap of 30.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while GEHC trades at $66.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas GEHC's P/E ratio is 14.61. In terms of profitability, NARI's ROE is -0.00%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, NARI is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for NARI.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
NARI vs PHG Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PHG has a market cap of 24.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PHG trades at $24.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PHG's P/E ratio is 14.26. In terms of profitability, NARI's ROE is -0.00%, compared to PHG's ROE of +0.10%. Regarding short-term risk, NARI is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NARI vs ZBH Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ZBH trades at $91.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ZBH's P/E ratio is 10.73. In terms of profitability, NARI's ROE is -0.00%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NARI is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NARI vs ABMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NARI's ROE is -0.00%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NARI is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NARI vs SWAV Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NARI's ROE is -0.00%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NARI is less volatile compared to SWAV. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
NARI vs PEN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PEN trades at $318.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PEN's P/E ratio is 83.25. In terms of profitability, NARI's ROE is -0.00%, compared to PEN's ROE of +0.11%. Regarding short-term risk, NARI is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
NARI vs SNN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SNN trades at $26.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SNN's P/E ratio is 18.17. In terms of profitability, NARI's ROE is -0.00%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NARI is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NARI vs BIO-B Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BIO-B trades at $385.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, NARI's ROE is -0.00%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, NARI is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NARI.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NARI vs ALGN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ALGN trades at $146.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ALGN's P/E ratio is 13.38. In terms of profitability, NARI's ROE is -0.00%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NARI is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NARI vs BIO Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BIO has a market cap of 10.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BIO trades at $381.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BIO's P/E ratio is 41.05. In terms of profitability, NARI's ROE is -0.00%, compared to BIO's ROE of +0.03%. Regarding short-term risk, NARI is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
NARI vs GMED Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while GMED trades at $74.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas GMED's P/E ratio is 16.79. In terms of profitability, NARI's ROE is -0.00%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NARI is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for NARI.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
NARI vs BRKR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BRKR trades at $64.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BRKR's P/E ratio is 32.25. In terms of profitability, NARI's ROE is -0.00%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, NARI is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
NARI vs BRKRP Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BRKRP has a market cap of 9.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BRKRP trades at $470.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BRKRP's P/E ratio is 255.66. In terms of profitability, NARI's ROE is -0.00%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, NARI is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BRKRP's competition here
Insulet Corp. (NASDAQ: PODD)
NARI vs PODD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PODD has a market cap of 9.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PODD trades at $136.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PODD's P/E ratio is 23.19. In terms of profitability, NARI's ROE is -0.00%, compared to PODD's ROE of +0.27%. Regarding short-term risk, NARI is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
NARI vs MASI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas MASI's P/E ratio is 44.43. In terms of profitability, NARI's ROE is -0.00%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NARI is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NARI.Check MASI's competition here
Glaukos Corporation (NYSE: GKOS)
NARI vs GKOS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while GKOS trades at $154.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas GKOS's P/E ratio is -180.02. In terms of profitability, NARI's ROE is -0.00%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NARI is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check GKOS's competition here
Haemonetics Corporation (NYSE: HAE)
NARI vs HAE Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while HAE trades at $105.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas HAE's P/E ratio is 21.02. In terms of profitability, NARI's ROE is -0.00%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NARI is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for NARI.Check HAE's competition here
Integer Holdings Corporation (NYSE: ITGR)
NARI vs ITGR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ITGR trades at $126.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ITGR's P/E ratio is 19.89. In terms of profitability, NARI's ROE is -0.00%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, NARI is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
NARI vs LIVN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while LIVN trades at $76.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas LIVN's P/E ratio is 18.20. In terms of profitability, NARI's ROE is -0.00%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, NARI is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check LIVN's competition here
Axonics, Inc. (NASDAQ: AXNX)
NARI vs AXNX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NARI's ROE is -0.00%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NARI is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for NARI.Check AXNX's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NARI vs IRTC Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while IRTC trades at $110.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas IRTC's P/E ratio is -256.70. In terms of profitability, NARI's ROE is -0.00%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, NARI is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for NARI.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
NARI vs NEOG Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while NEOG trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas NEOG's P/E ratio is 49.14. In terms of profitability, NARI's ROE is -0.00%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, NARI is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for NARI.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NARI vs TMDX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while TMDX trades at $85.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas TMDX's P/E ratio is 43.29. In terms of profitability, NARI's ROE is -0.00%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, NARI is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check TMDX's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NARI vs BFLY Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BFLY trades at $9.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BFLY's P/E ratio is -39.13. In terms of profitability, NARI's ROE is -0.00%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NARI is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BFLY's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NARI vs AXGN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AXGN trades at $43.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AXGN's P/E ratio is 114.18. In terms of profitability, NARI's ROE is -0.00%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NARI is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NARI vs UFPT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while UFPT trades at $295.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas UFPT's P/E ratio is 30.20. In terms of profitability, NARI's ROE is -0.00%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NARI is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
NARI vs NUVA Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NARI's ROE is -0.00%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NARI is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for NARI.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NARI vs INSP Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while INSP trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas INSP's P/E ratio is 31.06. In terms of profitability, NARI's ROE is -0.00%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NARI is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for NARI.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NARI vs ESTA Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ESTA trades at $65.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ESTA's P/E ratio is -52.36. In terms of profitability, NARI's ROE is -0.00%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, NARI is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
NARI vs NVCR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while NVCR trades at $15.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas NVCR's P/E ratio is -12.18. In terms of profitability, NARI's ROE is -0.00%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, NARI is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for NARI.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NARI vs ATEC Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ATEC trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ATEC's P/E ratio is -168.67. In terms of profitability, NARI's ROE is -0.00%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, NARI is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
NARI vs CNMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CNMD trades at $45.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CNMD's P/E ratio is 9.97. In terms of profitability, NARI's ROE is -0.00%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NARI is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
NARI vs HSKA Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NARI's ROE is -0.00%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NARI is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NARI.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NARI vs IART Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while IART trades at $16.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas IART's P/E ratio is 6.83. In terms of profitability, NARI's ROE is -0.00%, compared to IART's ROE of -0.01%. Regarding short-term risk, NARI is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for NARI.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NARI vs AVNS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NARI's ROE is -0.00%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NARI is less volatile compared to AVNS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check AVNS's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NARI vs SILK Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SILK's P/E ratio is -18.96. In terms of profitability, NARI's ROE is -0.00%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NARI is less volatile compared to SILK. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
NARI vs AORT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AORT trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AORT's P/E ratio is 37.75. In terms of profitability, NARI's ROE is -0.00%, compared to AORT's ROE of -0.01%. Regarding short-term risk, NARI is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check AORT's competition here
Paragon 28, Inc. (NYSE: FNA)
NARI vs FNA Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas FNA's P/E ratio is -19.83. In terms of profitability, NARI's ROE is -0.00%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NARI is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for NARI.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
NARI vs IRMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while IRMD trades at $85.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas IRMD's P/E ratio is 43.10. In terms of profitability, NARI's ROE is -0.00%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NARI is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check IRMD's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NARI vs TNDM Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while TNDM trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas TNDM's P/E ratio is -16.90. In terms of profitability, NARI's ROE is -0.00%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, NARI is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for NARI.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
NARI vs ENOV Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ENOV trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ENOV's P/E ratio is 5.29. In terms of profitability, NARI's ROE is -0.00%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, NARI is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ENOV's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NARI vs LMRI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, LMRI has a market cap of 981M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while LMRI trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas LMRI's P/E ratio is -19.86. In terms of profitability, NARI's ROE is -0.00%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NARI is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for NARI.Check LMRI's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NARI vs PRCT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PRCT has a market cap of 979M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PRCT trades at $17.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PRCT's P/E ratio is -8.87. In terms of profitability, NARI's ROE is -0.00%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, NARI is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PRCT's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
NARI vs BBNX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BBNX has a market cap of 967.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BBNX trades at $21.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BBNX's P/E ratio is -13.04. In terms of profitability, NARI's ROE is -0.00%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, NARI is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BBNX's competition here
Bioventus Inc. (NASDAQ: BVS)
NARI vs BVS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BVS has a market cap of 935.6M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BVS trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BVS's P/E ratio is 18.17. In terms of profitability, NARI's ROE is -0.00%, compared to BVS's ROE of +0.28%. Regarding short-term risk, NARI is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NARI vs CBLL Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CBLL has a market cap of 898.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CBLL trades at $23.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CBLL's P/E ratio is -13.46. In terms of profitability, NARI's ROE is -0.00%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, NARI is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CBLL's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NARI vs CSII Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CSII's P/E ratio is -20.83. In terms of profitability, NARI's ROE is -0.00%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NARI is less volatile compared to CSII. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NARI vs SIBN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SIBN has a market cap of 824.5M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SIBN trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SIBN's P/E ratio is -54.68. In terms of profitability, NARI's ROE is -0.00%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, NARI is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
NARI vs INMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, INMD has a market cap of 819.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while INMD trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas INMD's P/E ratio is 9.90. In terms of profitability, NARI's ROE is -0.00%, compared to INMD's ROE of +0.12%. Regarding short-term risk, NARI is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NARI vs VREX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas VREX's P/E ratio is 19.42. In terms of profitability, NARI's ROE is -0.00%, compared to VREX's ROE of +0.05%. Regarding short-term risk, NARI is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NARI vs AHCO Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AHCO has a market cap of 767.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AHCO trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AHCO's P/E ratio is 11.51. In terms of profitability, NARI's ROE is -0.00%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, NARI is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for NARI.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NARI vs AVR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, AVR has a market cap of 747.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while AVR trades at $7.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas AVR's P/E ratio is -3.96. In terms of profitability, NARI's ROE is -0.00%, compared to AVR's ROE of -0.78%. Regarding short-term risk, NARI is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for NARI.Check AVR's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NARI vs CTKB Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CTKB has a market cap of 729.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CTKB trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CTKB's P/E ratio is -29.93. In terms of profitability, NARI's ROE is -0.00%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, NARI is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NARI vs SRDX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NARI's ROE is -0.00%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NARI is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NARI.Check SRDX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NARI vs SSII Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SSII has a market cap of 590.4M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SSII trades at $2.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SSII's P/E ratio is -49.17. In terms of profitability, NARI's ROE is -0.00%, compared to SSII's ROE of -0.27%. Regarding short-term risk, NARI is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SSII's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NARI vs APEN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas APEN's P/E ratio is -9.43. In terms of profitability, NARI's ROE is -0.00%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NARI is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NARI vs KIDS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, KIDS has a market cap of 579.2M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while KIDS trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas KIDS's P/E ratio is -19.11. In terms of profitability, NARI's ROE is -0.00%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NARI is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NARI vs DCTH Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, DCTH has a market cap of 538.5M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while DCTH trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas DCTH's P/E ratio is 1560.00. In terms of profitability, NARI's ROE is -0.00%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, NARI is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for NARI.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NARI vs ZIMV Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NARI's ROE is -0.00%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, NARI is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NARI.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
NARI vs CERS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CERS has a market cap of 528M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CERS trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CERS's P/E ratio is -87.04. In terms of profitability, NARI's ROE is -0.00%, compared to CERS's ROE of -0.10%. Regarding short-term risk, NARI is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NARI vs TCMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, TCMD has a market cap of 512.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while TCMD trades at $22.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas TCMD's P/E ratio is 21.05. In terms of profitability, NARI's ROE is -0.00%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, NARI is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check TCMD's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NARI vs PACB Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PACB has a market cap of 503.2M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PACB trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PACB's P/E ratio is -3.95. In terms of profitability, NARI's ROE is -0.00%, compared to PACB's ROE of -49.62%. Regarding short-term risk, NARI is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PACB's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NARI vs SGHT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SGHT has a market cap of 485.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SGHT trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SGHT's P/E ratio is -15.95. In terms of profitability, NARI's ROE is -0.00%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, NARI is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SGHT's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
NARI vs NPCE Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, NPCE has a market cap of 479.4M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while NPCE trades at $14.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas NPCE's P/E ratio is -24.67. In terms of profitability, NARI's ROE is -0.00%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, NARI is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for NARI.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NARI vs CLPT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CLPT has a market cap of 444.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CLPT trades at $14.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CLPT's P/E ratio is -12.57. In terms of profitability, NARI's ROE is -0.00%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, NARI is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NARI vs SENS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SENS has a market cap of 417.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SENS trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SENS's P/E ratio is -4.48. In terms of profitability, NARI's ROE is -0.00%, compared to SENS's ROE of -1.66%. Regarding short-term risk, NARI is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NARI vs OFIX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, OFIX has a market cap of 381.6M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while OFIX trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas OFIX's P/E ratio is -6.15. In terms of profitability, NARI's ROE is -0.00%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, NARI is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
NARI vs CV Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CV has a market cap of 332.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CV trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CV's P/E ratio is -10.56. In terms of profitability, NARI's ROE is -0.00%, compared to CV's ROE of -1.78%. Regarding short-term risk, NARI is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NARI vs SMLR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NARI's ROE is -0.00%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, NARI is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NARI.Check SMLR's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NARI vs RCEL Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, RCEL has a market cap of 294.1M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while RCEL trades at $11.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas RCEL's P/E ratio is -8.22. In terms of profitability, NARI's ROE is -0.00%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, NARI is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for NARI.Check RCEL's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NARI vs TMCI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, TMCI has a market cap of 291.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while TMCI trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas TMCI's P/E ratio is -4.79. In terms of profitability, NARI's ROE is -0.00%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, NARI is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for NARI.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NARI vs CATX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while CATX trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas CATX's P/E ratio is -1.89. In terms of profitability, NARI's ROE is -0.00%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NARI is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NARI vs TLSI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, TLSI has a market cap of 267.2M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while TLSI trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas TLSI's P/E ratio is -2.58. In terms of profitability, NARI's ROE is -0.00%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, NARI is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for NARI.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NARI vs INFU Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, INFU has a market cap of 257.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while INFU trades at $12.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas INFU's P/E ratio is 31.10. In terms of profitability, NARI's ROE is -0.00%, compared to INFU's ROE of +0.15%. Regarding short-term risk, NARI is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for NARI.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NARI vs MGRM Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NARI's ROE is -0.00%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, NARI is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NARI.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
NARI vs ELMD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ELMD has a market cap of 231.4M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ELMD trades at $27.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ELMD's P/E ratio is 21.34. In terms of profitability, NARI's ROE is -0.00%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, NARI is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
NARI vs NVRO Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NARI's ROE is -0.00%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NARI is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for NARI.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
NARI vs PROF Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, PROF has a market cap of 209.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while PROF trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas PROF's P/E ratio is -5.88. In terms of profitability, NARI's ROE is -0.00%, compared to PROF's ROE of -0.56%. Regarding short-term risk, NARI is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for NARI.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
NARI vs RXST Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, RXST has a market cap of 192.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while RXST trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas RXST's P/E ratio is -4.12. In terms of profitability, NARI's ROE is -0.00%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NARI is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for NARI.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NARI vs BSGM Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NARI's ROE is -0.00%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, NARI is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for NARI.Check BSGM's competition here
Neuronetics, Inc. (NASDAQ: STIM)
NARI vs STIM Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, STIM has a market cap of 190.7M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while STIM trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas STIM's P/E ratio is -6.23. In terms of profitability, NARI's ROE is -0.00%, compared to STIM's ROE of -1.51%. Regarding short-term risk, NARI is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for NARI.Check STIM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NARI vs MDGS Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NARI's ROE is -0.00%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NARI is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for NARI.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NARI vs FOCL Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, FOCL has a market cap of 176.5M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while FOCL trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas FOCL's P/E ratio is -4.55. In terms of profitability, NARI's ROE is -0.00%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, NARI is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for NARI.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
NARI vs QSI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, QSI has a market cap of 165M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while QSI trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas QSI's P/E ratio is -1.81. In terms of profitability, NARI's ROE is -0.00%, compared to QSI's ROE of -0.47%. Regarding short-term risk, NARI is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for NARI.Check QSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NARI vs QIPT Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NARI's ROE is -0.00%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NARI is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NARI.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
NARI vs LUCD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, LUCD has a market cap of 157.6M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while LUCD trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas LUCD's P/E ratio is -2.23. In terms of profitability, NARI's ROE is -0.00%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, NARI is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for NARI.Check LUCD's competition here
Quanterix Corporation (NASDAQ: QTRX)
NARI vs QTRX Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, QTRX has a market cap of 154M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while QTRX trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas QTRX's P/E ratio is -1.29. In terms of profitability, NARI's ROE is -0.00%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, NARI is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for NARI.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
NARI vs INGN Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, INGN has a market cap of 145.1M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while INGN trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas INGN's P/E ratio is -5.89. In terms of profitability, NARI's ROE is -0.00%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NARI is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for NARI.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
NARI vs ICAD Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NARI's ROE is -0.00%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NARI is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NARI.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
NARI vs ECOR Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ECOR has a market cap of 100.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ECOR trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ECOR's P/E ratio is -6.62. In terms of profitability, NARI's ROE is -0.00%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, NARI is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NARI vs HJLI Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas HJLI's P/E ratio is N/A. In terms of profitability, NARI's ROE is -0.00%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, NARI is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for NARI.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
NARI vs ASXC Comparison September 2026
Inari Medical, Inc. (NASDAQ: NARI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NARI stands at 4.7B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, NARI is priced at $79.97 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NARI currently has a P/E ratio of -59.24, whereas ASXC's P/E ratio is -1.12. In terms of profitability, NARI's ROE is -0.00%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, NARI is less volatile compared to ASXC. This indicates lower risk in terms of short-term price fluctuations for NARI.Check ASXC's competition here